Steroidal alkaloids from Holarrhena antidysenterica as acetylcholinesterase inhibitors and the investigation for structure-activity relationships

详细信息	查看全文 | 推荐本文 |

• 作者：Zhong-Duo Yang^a ; ^{yangzhongduo@126.com} ; Dong-Zhu Duan^a ; Wei-Wei Xue^b ; Xiao-Jun Yao^b ; Shuo Li^c
• 关键词：Steroidal alkaloids ; Holarrhena antidysenterica ; Alzheimer's disease ; Acetylcholinesterase inhibitor ; Structure&ndash ; activity relationships ; Conessimin
• 刊名：Life Sciences
• 出版年：2012
• 期刊代码：62_00243205
• 类别：imm
• 出版时间：14 June, 2012
• 卷：90
• 期：23-24
• 页码：929-933
• 文件大小：581 K

摘要

Aims

Inhibition of acetylcholinesterase (AChE) is still considered as a strategy for the treatment of neurological disorders such as Alzheimer's disease (AD). Many plant derived alkaloids (such as huperzine A, galanthamine and rivastigmine) are known for their AChE inhibitory activity. The aim of the present work was to isolate and identify new AChE inhibitors from Holarrhen antidysenterica.

Main methods

These compounds were tested for AChE inhibiting activity by the Ellman's method in 96-well microplates. In addition, molecular modeling was performed to explore the binding mode of inhibitors 1-5 at the active site of AChE, and the preliminary structure-activity relationships (SARs) were discussed.

Key findings

In the course of searching for AChE inhibitors from herb medicines, the total alkaloidal extract from the seeds of H. antidysenterica was found having potent AChE inhibitory activity with an IC₅₀ value of 6.1 渭g/mL. Further bioactivity-guided chromatographic fractionation afforded five steroidal alkaloids, conessine 1, isoconessimine 2, conessimin 3, conarrhimin 4 and conimin 5. All the isolated compounds, except for 2, showed strong AChE inhibiting activity with IC₅₀ values ranging from 4 to 28 渭M. The most active inhibitor is compound 3 with an IC₅₀ value of 4 渭M. The mode of AChE inhibition by 3 was reversible and non-competitive.

Significance

The results suggest that these alkaloids could be potential candidates for further development of new drugs against AD.